Faculty Directory

Preclinical evaluation of a novel topoisomerase inhibitor in melanoma cells. As principle investigator on support received from the Jimmy Totman Foundation, I worked with Jawad Francis* a postdoctoral fellow to evaluate the efficacy of combining a novel topoisomerase inhibitor with mitogen activated protein kinase inhibitors or indoleamine-2,3-dioxygenase inhibitors to manage melanoma. ( 11/2006 - 7/2008 )

Funded Research Project (CI)

DNA Base-Pairing and Mutagenesis ( 12/1988 - 11/2009 )

Non-Funded Research Project

Mechanisms of anticancer activity for the anticancer drug candidates Aminoflavone and 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole ( 7/2005 - 9/2006 )

Mechanisms of redox regulation of anticancer activity of novel aryl hydrocarbon receptor agonists. Co-investigators: Willie Davis, Ph.D., Lancelot McLean, Ph.D.*Cheri Watkins* ( 9/2005 - Present )

Our current research project focuses on the role oxidative stress and related signaling pathways play in mediating the anticancer activity of novel aryl hydrocarbon receptor agonists. In particular, our group evaluates the role redox signaling pathways play in mediating DNA damage and apoptosis induced by aryl hydrocarbon receptor agonists.